Prolific Machines Secures $55 Million Investment for Its Photomolecular Biology Platform
Based in California and operating in Turkey, Prolific Machines has secured a significant $55 million in funding through a Series B1 round led by The Ki Tua Fund, the venture capital arm of Fonterra. The company was founded in 2020 by Deniz Kent, Max Huisman, and Declan Jones, with the aim of developing sustainable and efficient solutions in food and pharmaceutical production using photomolecular technology.

Based in California and operating in Turkey, Prolific Machines has secured a significant $55 million in funding through a Series B1 round led by The Ki Tua Fund, the venture capital arm of Fonterra. The company was founded in 2020 by Deniz Kent, Max Huisman, and Declan Jones, with the aim of developing sustainable and efficient solutions in food and pharmaceutical production using photomolecular technology. This innovative technology utilizes light to control and grow cells, paving the way for more sustainable and efficient manufacturing processes in these critical industries.
Joining this investment round were notable firms such as BreakthroughEnergy Ventures, Mayfield, SOSV, Shorewind Capital, Darco Capital, Conti Ventures, and In-Q-Tel (IQT), all of which are stakeholders in the push towards innovative and sustainable technologies.
Deniz Kent, Co-founder and CEO of Prolific Machines, highlighted the capabilities of their platform: “Photomolecular biology allows for the precise control and optimization of cellular behavior using light and artificial intelligence, enabling the efficient production of superior bio-solutions across a wide spectrum from food to pharmaceuticals.”
Kent further explained the company's vision, stating, “We embarked on this journey with a vision to use light, one of our most abundant resources, to create exponentially better ways to control biology. This control is crucial for producing cheaper and higher-quality products.”
With the new funding, Prolific Machines plans to commercialize its photomolecular platform through industry partnerships, significantly expanding its reach into the food and pharmaceutical sectors. This move is expected to strengthen the company’s position in the global biotechnology market and contribute substantially to its future growth. The technological advancements from Prolic Machines promise to bring about more economical and environmentally friendly production processes, marking a significant step forward for the industry.